Managing the high-risk patient: Therapeutic approaches in 2002

Atherosclerosis Supplements

Volumn 4, Issue 1, 2003, Pages 15-20

  Schuster, Herbert ^a  

^a HUMBOLDT UNIVERSITY   (Germany)

Author keywords

Cardiovascular disease risk; Heterozygous familial hypercholesterolemia; Lipid lowering therapy; Type 2 diabetes

Indexed keywords

ANTILIPEMIC AGENT; ATORVASTATIN; CHOLESTEROL; FENOFIBRATE; GEMFIBROZIL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; ROSUVASTATIN; SIMVASTATIN; TRIACYLGLYCEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CONFERENCE PAPER; DISEASE ASSOCIATION; DYSLIPIDEMIA; FAMILIAL HYPERCHOLESTEROLEMIA; FOLLOW UP; HIGH RISK PATIENT; HUMAN; ISCHEMIC HEART DISEASE; LIPID ANALYSIS; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; RANDOMIZATION; TREATMENT OUTCOME; CORONARY ARTERY DISEASE; DISEASE MANAGEMENT; HYPERLIPOPROTEINEMIA TYPE 2; METABOLISM; PRACTICE GUIDELINE; REVIEW; RISK FACTOR;

ANTILIPEMIC AGENTS; CHOLESTEROL, LDL; CORONARY DISEASE; DIABETES MELLITUS, TYPE 2; DISEASE MANAGEMENT; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERLIPOPROTEINEMIA TYPE II; RISK FACTORS;

EID: 0141449126     PISSN: 15675688     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1567-5688(03)00005-9     Document Type: Conference Paper

References (27)

1. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). J Am Med Assoc 2001;285:2486-97.
2. Shepherd J., Cobbe S.M., Ford I., Isles C.G., Lorimer A.R., MacFarlane P.W., McKillop J.H., Packard C.J. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N. Engl. J. Med. 333:1995;1301-1307.
3. Downs J.R., Clearfield M., Weis S., Whitney E., Shapiro D.R., Beere P.A., Langendorfer A., Stein E.A., Kruyer W., Gotto A.M. Jr. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels. JAMA. 279:1998;1615-1622.
4. Randomised trial of cholesterol lowering in 4444 patients with CHD: the Scandinavian Simvastatin Survival Study (4S). Lancet. 344:1994;1383-1389.
5. Sacks F.M., Pfeffer M.A., Moye L.A., Rouleau J.L., Rutherford J.D., Cole T.G., Brown L., Warnica J.W., Arnold J.M., Wun C.C., Davis B.R., Braunwald E. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N. Engl. J. Med. 335:1996;1001-1009.
6. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N. Engl. J. Med. 339:1998;1349-1357.
7. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomised placebo-controlled trial. Lancet. 360:2002;7-22.
8. Pyorälä K., Laakso M., Uusitupa M. Diabetes and atherosclerosis: an epidemiologic overview. Diabetes Metab. Rev. 3:1987;463-524.
9. Beckman J.A., Creager M.A., Libby P. Diabetes and atherosclerosis. Epidemiology, pathophysiology, and management. JAMA. 287:2002;2570-2581.
10. Haffner S.M., Lehto S., Ronnemaa T., Pyorala K., Laakso M. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N. Engl. J. Med. 339:1998;229-234.
11. Management of dyslipidaemia in adults with diabetes. Diabetes Care. 24:(Suppl. 1):2001;S58-61.
12. Dyslipidaemia in type 2 diabetes: a panel discussion. Pract Diab Int 2002;19 (Suppl):S1-6.
13. Harris M.I. Health care and health care status and outcomes for patients with type 2 diabetes. Diabetes Care. 23:2000;754-758.
14. Pyorälä K., Pedersen T.R., Kjekshus J., Faergeman O., Olsson A.G., Thorgeirsson G. Cholesterol lowering with simvastatin improves prognosis of diabetic patients with coronary heart disease. A subgroup analysis of the Scandinavian Simvastatin Survival Study (4S). Diabetes Care. 20:1997;614-620.
15. Sacks F.M., Tonkin A.M., Shepherd J., Braunwald E., Cobbe S., Hawkins C.M., Keech A., Packard C., Simes J., Byington R., Furberg C. Effect of pravastatin on coronary disease events in subgroups defined by coronary risk factors. The Prospective Pravastatin Pooling Project. Circulation. 102:2000;1893-1900.
16. Rubins H.B., Sander J.R., Collins D., Fye C.L., Anderson J.W., Elam M.B., Faas F.H., Linares E., Schaefer E.J., Schectman G., Wilt T.J., Wittes J. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. N. Engl. J. Med. 341:1999;410-418.
17. Athyros V.G., Papageorgiou A.A., Athyrou V.V., Demitriadis D.S., Kontopoulos A.G. Atorvastatin and micronized fenofibrate alone and in combination in type 2 diabetes with combined hyperlipidemia. Diabetes Care. 25:2002;1198-1202.
18. Durrington P., Hamann A., Tuomilehto J., Smith K., Kallend D. Rosuvastatin alone and in combination with fenofibrate in hyperlipidaemic patients with type 2 diabetes. Diabetologia. 44:(Suppl. 1):2001;A165. Abstract 631.
19. Slack J. Risks of ischemic heart disease in familial hyperlipoproteinemic states. Lancet. 2:1969;1380-1382.
20. Stone N.J., Levy R.I., Fredrickson D.S., Verter J. Coronary artery disease in 116 kindreds with familial type II hyperlipoproteinemia. Circulation. 49:1974;476-488.
21. Williams R.R., Hunt S.C., Schumacher M.C., Hegele R.A., Leppert M.F., Ludwig E.H., Hopkins P.N. Diagnosing heterozygous familial hypercholesterolemia using new practical criteria validated by molecular genetics. Am. J. Cardiol. 72:1993;171-176.
22. Stein E., Kreisberg R., Miller V., Mantell G., Washington L., Shapiro D.R. Effects of simvastatin and cholestyramine in familial and nonfamilial hypercholesterolemia. Arch. Intern. Med. 150:1990;341-345.
23. Stein E.A., Davidson M.H., Dujovne C.A., Hunninghake D.B., Goldberg R.B., Illingworth D.R., Knopp R.H., Miller V.T., Frost P., Isaacsohn J.L., Mitchel Y.B., Melino M.R., Shapiro D., Tobert J.A. Efficacy and tolerability of low dose simvastatin and niacin, alone and in combination, in patients with combined hyperlipidemia: a prospective trial. J. Cardiovasc. Pharmacol. Ther. 1:1996;107-116.
24. Kane J.P., Malloy M.J., Ports T.A., Phillips N.R., Diehl J.C., Havel R.J. Regression of coronary atherosclerosis during treatment of familial hypercholesterolemia with combined drug regimens. JAMA. 264:1990;3007-3012.
25. Smilde T.J., van Wissen S., Wollersheim H., Trip M.D., Kastelein J.J.P., Stalenhoef A.F.H. Effect of aggressive versus conventional lipid lowering on atherosclerosis progression in familial hypercholesterolaemia (ASAP): a prospective, randomised, double-blind trial. Lancet. 357:2001;577-581.
26. Stein E., Strutt K.L., Miller E., Southworth H. ZD4522 is superior to atorvastatin in the treatment of patients with heterozygous familial hypercholesterolemia. J. Am. Coll. Cardiol. 37:(Suppl. A):2001;292A. Abstract 1261-176.
27. Stein E., Strutt K.L., Miller E., Southworth H. Rosuvastatin (20, 40 and 80 mg) reduces LDL-C, raises HDL-C and achieves treatment goals more effectively than atorvastatin (20, 40 and 80 mg) in patients with heterozygous familial hypercholesterolaemia. Atheroscler. (Suppl.). 2:2001;90. Abstract P176.